Skip to main content
. 2022 May 18;12:8313. doi: 10.1038/s41598-022-12003-z

Figure 2.

Figure 2

(a) FBA concentration in stool samples collected on enrolment to the study in the 4 different study groups—FBA faecal bile acids, BAD bile acid diarrhoea, CD +ve Crohn’s disease patients with a positive SeHCAT scan, PC +ve post-cholecystectomy patients with a positive SeHCAT scan, PC −ve post-cholecystectomy patients with a negative SeHCAT scan, CG SeHCAT-negative control group. The total number of patients and the median and interquartile range (IQR)s from each cohort are also listed. (b) Faecal bile acid (FBA) concentration in stool samples collected on enrolment to the study split into SeHCAT result where < 5% indicates severe BAD, 5–10% moderate, 10–15% mild and > 15% as normal result. The total number of patients and median and interquartile ranges (IQR) from each group are also listed. *p < 0.05, **p < 0.01 and ***p < 0.001.